Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital Zhejiang UniversityNo recent work listed

Lisong Teng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6470-9017; OpenAlex author ID A5029765784. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
7
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper

Papers 3

  1. MiR-199 Reverses the Resistance to Gemcitabine in Pancreatic Cancer by Suppressing Stemness through Regulating the Epithelial-Mesenchymal Transition. Last author DOI 10.1021/acsomega.1c02945↗
  2. Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target. Last author DOI 10.3892/ijo.2020.4965↗
  3. New path to treating pancreatic cancer: TRAIL gene delivery targeting the fibroblast-enriched tumor microenvironment. Co-author DOI 10.1016/j.jconrel.2018.07.047↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jinxiao Liang · 1 shared paper, 2021 · strength 0.17
  2. Liang Wang · 1 shared paper, 2021 · strength 0.17
  3. Weitian Wei · 1 shared paper, 2021 · strength 0.17
  4. Xiaoxiao Du · 1 shared paper, 2020 · strength 0.12
  5. Haiping Jiang · 1 shared paper, 2018 · strength 0.08
  6. Youqing Shen · 1 shared paper, 2018 · strength 0.08
  7. Xiangrui Liu · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.